Last Updated on January 4, 2024 by The Health Master
USFDA Inspection
In the dynamic pharmaceutical landscape, Gland Pharma has recently made waves with a significant announcement. The company proudly shared that it has received an Establishment Inspection Report (EIR) from the USFDA, signifying the successful closure of the USFDA inspection at its Pashamylaram Facility in Hyderabad.
Let’s delve into the details of this notable achievement and what it means for Gland Pharma’s future.
Background of Gland Pharma
Established in 1978 in Hyderabad, Gland Pharma has solidified its position as a prominent player in the pharmaceutical industry.
Specializing in generic injectables, the company boasts a diverse range of products, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions.
USFDA Inspection Details
The meticulous USFDA inspection occurred between August 23, 2023, and August 26, 2023.
Focused on the Quality System and Current Good Manufacturing Practice regulations for Medical Devices (21 CFR Part 820), the inspection aimed to ensure compliance with stringent industry standards.
Announcement of EIR Receipt
Gland Pharma promptly shared the positive news through a filing with the Bombay Stock Exchange (BSE). In the statement, the company confirmed the receipt of the Establishment Inspection Report, officially marking the conclusion of the inspection.
Significance of EIR
The EIR holds immense significance in the pharmaceutical realm. It serves as a testament to a company’s commitment to quality and adherence to regulatory requirements.
For Gland Pharma, this achievement not only validates its practices but also instills confidence in stakeholders and the industry at large.
Quality Assurance Practices at Pashamylaram Facility
The Pashamylaram Facility in Hyderabad, where the inspection took place, is a crucial component of Gland Pharma’s manufacturing capabilities.
The successful inspection underscores the company’s robust quality assurance practices, ensuring the production of safe and reliable pharmaceuticals.
Implications for Gland Pharma
The closure of the USFDA inspection brings forth positive implications for Gland Pharma. It not only solidifies the company’s reputation for quality but may also result in increased trust from consumers, partners, and investors.
Gland Pharma’s Product Portfolio
Gland Pharma’s extensive product portfolio is a testament to its commitment to addressing diverse medical needs.
The company’s offerings encompass a wide array of pharmaceutical solutions, showcasing its versatility and expertise in the field.
Timeline of Gland Pharma’s Growth
Since its inception in 1978, Gland Pharma has achieved significant milestones.
A timeline highlighting key moments in the company’s growth journey showcases its resilience and adaptability in the ever-evolving pharmaceutical landscape.
USFDA Regulations for Medical Devices
The inspection at the Pashamylaram Facility specifically focused on compliance with USFDA regulations for Medical Devices.
Understanding these regulations provides insight into the meticulous standards upheld by Gland Pharma.
FAQs
- What does the Establishment Inspection Report (EIR) signify for Gland Pharma?
- The EIR signifies the successful closure of the USFDA inspection, validating Gland Pharma’s adherence to quality and regulatory standards.
- How does the inspection outcome impact Gland Pharma’s reputation?
- The positive outcome enhances Gland Pharma’s reputation, fostering trust among consumers, partners, and investors.
- Can you elaborate on the significance of the USFDA regulations for Medical Devices?
- The regulations ensure that companies comply with strict standards, emphasizing the safety and efficacy of medical devices.
- What is the scope of Gland Pharma’s pharmaceutical product portfolio?
- Gland Pharma offers a diverse range of products, including injectables, vials, ampoules, pre-filled syringes, and more.
- How does Gland Pharma plan to leverage this success for future growth?
- While specific plans may not be detailed, the positive inspection outcome positions Gland Pharma for potential growth opportunities in the pharmaceutical sector
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA Inspection completed at Aurobindo Pharma Arm : Telangana
USFDA issues Form 483 with 10 observations to Dr Reddy’s Lab
USFDA issues EIR For Piramal Pharma Bethlehem Facility
USFDA issues Form 483 with 9 observations to Panacea: Baddi
USFDA issues Form 483 with 9 observation to Dr Reddy’s laboratories: Hyderabad
Medicines for these 4 Rare Diseases become cheaper
Videography During Inspections at Pharma Firms: Proposal
Drugs Control Dept’s fight against Antimicrobial Resistance: Karnataka
Excipient Equation: Balancing Safety and Quality in Drug Formulations
Gist of 31 Chapters on Schedule M
CDSCO Guidelines on Drug Recall
Govt Job: For Research Scientist in CDSCO, Pay upto Rs. 84k pm
Pharma Innovation in India: A Call to Action – DCGI
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
